[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-353600-105":59,"doc-detail-353600-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","brake-and-accelerator-revisiting-tumor-cell-direct-responses-and-the-paradox-of-aggression-in-anti-vegf-therapy","“Brake” and “accelerator” - revisiting tumor cell direct responses and the paradox of aggression in anti-VEGF therapy","","Targeted anti-angiogenic therapies against VEGF are standard treatments for advanced cancers, yet clinical benefits are constrained by acquired resistance and, in some cases, paradoxical tumor aggressiveness with accelerated metastasis. This work analyzes receptor tyrosine kinase interactions and pathway rewiring to propose an integrated “brake-accelerator” model, where VEGF blockade releases a brake on bypass signaling, enabling invasive transformation and immune evasion. It highlights direct signal remodeling, frames tumor evolution as a tripartite stress response, and outlines molecular and clinical implications for adaptive combination strategies and dynamic biomarkers.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/brake-and-accelerator-revisiting-tumor-cell-direct-responses-and-the-paradox-of-aggression-in-anti-vegf-therapy/353600/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/brake-and-accelerator-revisiting-tumor-cell-direct-responses-and-the-paradox-of-aggression-in-anti-vegf-therapy/353600.png","ImageObject",300,407,{"name":92,"@type":93},"Eliana","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-05","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":29},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why does anti-VEGF therapy sometimes lead to paradoxical tumor aggressiveness?","Question",{"text":112,"@type":113},"Although anti-VEGF treatment can initially control tumors, acquired resistance may activate programs that promote invasion and distant metastatic potential.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What is the proposed “brake-accelerator” model?",{"text":117,"@type":113},"In the presence of VEGF, receptor complex “brakes” restrict bypass pathway activity; VEGF blockade releases the brake and amplifies escape “accelerators,” driving invasive transformation and immune evasion.",{"name":119,"@type":110,"acceptedAnswer":120},"What molecular features does the paper emphasize for this mechanism?",{"text":121,"@type":113},"The model centers on tumor-cell direct signal remodeling, regulatory roles of VEGFR2–MET complexes, the signal-hub function of neuropilin, and the networked characteristics of escape pathways.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},353600,1790463871,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":29,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},4398048949847,"https://ap-avatar.wpscdn.com/avatar/400002536579ef2da7f?_k=1778318612642679267","TYPE Perspective  \nPUBLISHED 16 January 2026  \nDOI 10.3389/fimmu.2025.1718894  \nOPEN ACCESS  \nEDITED BY  \nChunsik Lee,  \nGEMCRO, Republic of Korea  \nREVIEWED BY  \nRong Ju,  \nSun Yat-sen University, China Anil Kumar,  \nAdichunchanagiri University, India  \n*CORRESPONDENCE  \nZhiyong Wang  \n[wangzhiyong@zmuzh.edu.cn](wangzhiyong@zmuzh.edu.cn)  \nRECEIVED 04 October 2025  \nREVISED 27 December 2025  \nACCEPTED 29 December 2025  \nPUBLISHED 16 January 2026  \nCITATION  \nWei P, Li J, Cheng X, Lu Y, Xia Q and Wang Z (2026) “Brake” and “accelerator” : revisiting tumor cell direct responses and the paradox of aggression in anti-VEGF therapy.  \nFront. Immunol. 16:1718894 .  \ndoi: 10.3389/fimmu.2025.1718894  \nCOPYRIGHT  \n© 2026 Wei, Li, Cheng, Lu, Xia and Wang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY) . The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.  \n“Brake” and “accelerator”: revisiting tumor cell direct responses and the paradox of aggression in anti-VEGF therapy  \nPei Wei, Jiaqi Li, Xueyan Cheng, Yanxin Lu, Qiang Xia and Zhiyong Wang*  \nDepartment of Immunology, Zunyi Medical University, Zhuhai, China  \nTargeted anti-angiogenic therapies against vascular endothelial growth factor (VEGF) are standard treatments for various advanced cancers. However, their clinical beneﬁts are often limited by acquired resistance, with some patients even exhibiting paradoxical tumor aggressiveness and accelerated metastasis. Traditional views primarily attribute this to hypoxia-driven mechanisms within the tumor microenvironment. Based on an analysis of receptor tyrosine kinase (RTK) interactions and pathway rewiring within tumor cells, this paper proposesan integrated “brake-accelerator” model. We posit that in the presence of VEGF, VEGFR2–Mesenchymal-Epithelial Transition factor (MET) heterocomplexes and neuropilin (NRP) co-receptors restrict bypass pathway activity. Upon VEGF blockade, this “brake” is released, and bypass “accelerators” are passively or actively ampliﬁed, collectively driving invasive transformation and immune evasion. We identify “direct signal remodeling” in tumor cells as a potentially underappreciated contributor. This process acts as a potential upstream integration node that, alongside treatment-induced hypoxic stress and immune–stromal microenvironment remodeling, constitutes a “tripartite stress ” framework. Through Darwinian clonal selection and induced phenotypic plasticity, this framework drives the evolution of tumors towards amore aggressive phenotype. This paper systematically reviews the molecular mechanisms supporting this model, including the regulatory role of VEGFR2-MET complexes, the signal hub function of NRP, and the networked characteristics of escape pathways. Finally, we discuss the implications of this conceptual model for future clinical practice, including the development of dynamic biomarkers based on intrinsic tumor cell characteristics and the design of more precise combination and adaptive treatment strategies to overcome resistance to anti-VEGF therapy and improve patient prognosis.  \nKEYWORDS  \nanti-VEGF therapy, direct signal remodeling, paradox of aggression, therapeutic resistance, vascular endothelial growth factor  \nFrontiers in Immunology 01 [frontiersin.org](frontiersin.org)  \n1 Introduction  \nInhibition of tumor angiogenesis has been one of the most signiﬁcant advances in oncology over the past two decades (1–3) . Anti-angiogenic agents, exempliﬁed by the humanized anti-VEGFA monoclonal antibody bevacizumab, have become a cornerstone of treatment for various solid tumors, including colorectal cancer (CRC) (4, 5), non-small cell lung cancer (NSC","cbCaidtImXLSFK7V","https://ap.wps.com/l/cbCaidtImXLSFK7V","pdf",675506,13,"English","# Introduction\n## Anti-angiogenic therapy and acquired resistance\n## Paradox of aggression after anti-VEGF therapy\n## Proposed mechanistic models for resistance","[{\"question\":\"Why does anti-VEGF therapy sometimes lead to paradoxical tumor aggressiveness?\",\"answer\":\"Although anti-VEGF treatment can initially control tumors, acquired resistance may activate programs that promote invasion and distant metastatic potential.\"},{\"question\":\"What is the proposed “brake-accelerator” model?\",\"answer\":\"In the presence of VEGF, receptor complex “brakes” restrict bypass pathway activity; VEGF blockade releases the brake and amplifies escape “accelerators,” driving invasive transformation and immune evasion.\"},{\"question\":\"What molecular features does the paper emphasize for this mechanism?\",\"answer\":\"The model centers on tumor-cell direct signal remodeling, regulatory roles of VEGFR2–MET complexes, the signal-hub function of neuropilin, and the networked characteristics of escape pathways.\"}]","“Brake” and “accelerator” - revisiting tumor cell direct responses and the paradox of aggression in anti-VEGF therapy | PDF",1790106246,33,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9c92c53818d7240bfaa09c5ed8206306.webp",983,1389,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c39f1f92c5fb2170fd28e8679afea1c0.webp",982,1388,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/40543f7ee01e288ce4f7a7dd9a1b36b8.webp",981,1386,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ecb35aba526b153e19e3497e1d46340a.webp",980,1385]